Rasagiline-induced delay of retinal ganglion cell death in experimental glaucoma in rats

Journal of Glaucoma

Volumn 20, Issue 5, 2011, Pages 273-277

  Levkovitch Verbin, Hani ^a,b   Vander, Shelly ^a,b   Melamed, Shlomo ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

glaucoma; neuroprotection; rasagiline; retinal ganglion cells

Indexed keywords

FLUOROGOLD; RASAGILINE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; CELL DAMAGE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFECT; ENUCLEATION; GLAUCOMA; INTRAOCULAR PRESSURE; LASER COAGULATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; RETINA; RETINA GANGLION CELL; SUPERIOR COLLICULUS; WISTAR RAT;

ANIMALS; CELL COUNT; CELL SURVIVAL; DISEASE MODELS, ANIMAL; GLAUCOMA; INDANS; INJECTIONS, INTRAPERITONEAL; INTRAOCULAR PRESSURE; MONOAMINE OXIDASE INHIBITORS; NEUROPROTECTIVE AGENTS; RATS; RATS, WISTAR; RETINAL GANGLION CELLS;

EID: 79958818174     PISSN: 10570829     EISSN: 1536481X     Source Type: Journal    
DOI: 10.1097/IJG.0b013e3181e3d101     Document Type: Article

References (34)

1. Quigley HA. New paradigms in the mechanisms and management of glaucoma. Eye. 2005;19:1241-1248. (Pubitemid 43148496)
2. Guay DR. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. Am J Geriatr Pharmacother. 2006;4:330-346. (Pubitemid 46222213)
3. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol. 2002;59:1937-1943.
4. Akao Y, Maruyama W, Yi H, et al. An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett. 2002;326:105-108.
5. Eliash S, Dror V, Cohen S, et al. Neuroprotection by rasagiline in thiamine deficient rats. Brain Res. 2009;1256:138-148.
6. Eliash S, Speiser Z, Cohen S. Rasagiline and its (S) enantiomer increase survival and prevent stroke in salt-loaded stroke-prone spontaneously hypertensive rats. J Neural Transm. 2001;108:909-923. (Pubitemid 32802090)
7. Speiser Z, Katzir O, Rehavi M, et al. Sparing by rasagiline (TVP-1012) of cholinergic functions and behavior in the postnatal anoxia rat. Pharmacol Biochem Behav. 1998;60:387-393. (Pubitemid 28282679)
8. Speiser Z, Levy R, Cohen S. Effects of N-propargyl- 1-(R)aminoindan (rasagiline) in models of motor and cognition disorders. J Neural Transm Suppl. 1998;52:287-300.
9. Speiser Z, Mayk A, Eliash S, et al. Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat. J Neural Transm. 1999;106:593-606. (Pubitemid 29401349)
10. Speiser Z, Mayk A, Litinetsky L, et al. Rasagiline is neuroprotective in an experimental model of brain ischemia in the rat. J Neural Transm. 2007;114:595-605. (Pubitemid 46664052)
11. Stefanova N, Poewe W, Wenning GK. Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Exp Neurol. 2008;210:421-427.
12. Youdim MB, Wadia A, Tatton W, et al. The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann N Y Acad Sci. 2001;939:450-458. (Pubitemid 32620098)
13. Mandel S, Weinreb O, Amit T, et al. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res Brain Res Rev. 2005;48:379-387. (Pubitemid 40590050)
14. Youdim MB, Weinstock M. Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL) -ethyl methyl carbamate]. Cell Mol Neurobiol. 2001;21:555-573. (Pubitemid 34538855)
15. Weinreb O, Amit T, Sagi Y, et al. Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson's disease drug, rasagiline compared with selegiline, in the rat midbrain. J Neural Transm. 2009;116:1457-1472.
16. Weinreb O, Amit T, Bar-Am O, et al. Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathway. Ann N Y Acad Sci. 2005;1053:348-355. (Pubitemid 43031115)
17. Tatton WG. Apoptotic mechanisms in neurodegeneration: possible relevance to glaucoma. Eur J Ophthalmol. 1999;9(suppl 1):S22-S29. (Pubitemid 29179931)
18. Ragaiey T, Ma JX, Jiang WJ, et al. L-deprenyl protects injured retinal precursor cells in vitro. J Ocul Pharmacol Ther. 1997;13:479-488. (Pubitemid 28090240)
19. Levkovitch-Verbin H, Quigley HA, Martin KR, et al. Translimbal laser photocoagulation to the trabecular mesh-work as a model of glaucoma in rats. Invest Ophthalmol Vis Sci. 2002;43:402-410. (Pubitemid 34113222)
20. Blair M, Pease ME, Hammond J, et al. Effect of glatiramer acetate on primary and secondary degeneration of retinal ganglion cells in the rat. Invest Ophthalmol Vis Sci. 2005;46:884-890. (Pubitemid 41321024)
21. Levkovitch-Verbin H, Quigley HA, Martin KR, et al. A model to study differences between primary and secondary degeneration of retinal ganglion cells in rats by partial optic nerve transection. Invest Ophthalmol Vis Sci. 2003;44:3388-3393. (Pubitemid 36909775)
22. Danias J, Shen F, Goldblum D, et al. Cytoarchitecture of the retinal ganglion cells in the rat. Invest Ophthalmol Vis Sci. 2002;43:587-594. (Pubitemid 34184471)
23. Hanninen VA, Pantcheva MB, Freeman EE, et al. Activation of caspase 9 in a rat model of experimental glaucoma. Curr Eye Res. 2002;25:389-395.
24. McKinnon SJ, Lehman DM, Kerrigan-Baumrind LA, et al. Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. Invest Ophthalmol Vis Sci. 2002;43:1077-1087. (Pubitemid 34258276)
25. Levkovitch-Verbin H, Harizman N, Dardik R, et al. Regulation of cell death and survival pathways in experimental glaucoma. Exp Eye Res. 2007;85:250-258. (Pubitemid 47096643)
26. Levkovitch-Verbin H, Dardik R, Vander S, et al. Experimental glaucoma and optic nerve transection induce simultaneous upregulation of proapoptotic and prosurvival genes. Invest Ophthalmol Vis Sci. 2006;47:2491-2497. (Pubitemid 351639832)
27. Weinreb O, Amit T, Bar-Am O, et al. Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy. Ann N Y Acad Sci. 2007;1122:155-168. (Pubitemid 350249546)
28. Pease ME, McKinnon SJ, Quigley HA, et al. Obstructed axonal transport of BDNF and its receptor TrkB in experimental glaucoma. Invest Ophthalmol Vis Sci. 2000;41:764-774. (Pubitemid 30158887)
29. Quigley HA, McKinnon SJ, Zack DJ, et al. Retrograde axonal transport of BDNF in retinal ganglion cells is blocked by acute IOP elevation in rats. Invest Ophthalmol Vis Sci. 2000;41:3460-3466.
30. Martin KR, Quigley HA, Zack DJ, et al. Gene therapy with brain-derived neurotrophic factor as a protection: retinal ganglion cells in a rat glaucoma model. Invest Ophthalmol Vis Sci. 2003;44:4357-4365. (Pubitemid 37186270)
31. Ko ML, Hu DN, Ritch R, et al. The combined effect of brain-derived neurotrophic factor and a free radical scavenger in experimental glaucoma. Invest Ophthalmol Vis Sci. 2000;41:2967-2971.
32. Ko ML, Hu DN, Ritch R, et al. Patterns of retinal ganglion cell survival after brain-derived neurotrophic factor administration in hypertensive eyes of rats. Neurosci Lett. 2001;305:139-142. (Pubitemid 33762785)
33. Youdim MB. The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30. Curr Alzheimer Res. 2006;3:541-550. (Pubitemid 46066429)
34. Weinreb O, Mandel S, Bar-Am O, et al. Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs. Neurotherapeutics. 2009;6:163-174.